



Foot and Mouth Disease Virus Vaccines Developments

Guest Editors:

Dr. Katherine Pflaum

Foreign Animal Disease Research
Unit, United States Department
of Agriculture, Agricultural
Research Service, Plum Island
Animal Disease Center,
Greenport, NY 11944, USA

Dr. Wilna Vosloo

Australian Centre for Disease
Preparedness, CSIRO-Health &
Biosecurity, 5 Portarlington
Road, Geelong, VIC 3220,
Australia

Deadline for manuscript
submissions:

closed (16 June 2023)

Message from the Guest Editors

Foot-and-mouth disease virus (FMDV) is a highly contagious viral infection of cloven-hoofed animals. FMDV outbreaks cause significant and devastating economic impacts worldwide. The most effective and widely accepted way to respond to outbreaks is through the use of chemically inactivated vaccination of domestic livestock. However, these inactivated vaccines are slow-acting and do not always permit a distinction between infected and vaccinated animals. Therefore, it is essential to develop new rapid vaccines and control strategies that could confer early protection and rapidly stop disease spread.

This Special Issue will cover the FMDV determinant of replication and pathogenesis and how this information facilitates next-generation FMDV vaccine and biotherapeutic developments. We particularly encourage the submission of manuscripts focused on improved control strategies addressing important gaps in the current inactivated FMDV vaccine including, but not limited to, duration of immunity, cross-reactivity, correlates of protection, early protection, antigen load, immunization responses, and safer marker vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com